Can-Fite BioPharma Ltd. (CANF)

2,0900 -0,0518 (-2,42 %) À la clôture : 03:58PM EDT

Can-Fite BioPharma Ltd.

26 Ben Gurion Street
Ramat Gan 5257346
Israel
972 3 924 1114
https://www.canfite.com

Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 8

Dirigeants clés

Nom	Titre	Payer	Exercé	Année de naissance
Dr. Pnina Fishman Ph.D.	Founder, Chief Scientific Officer & Executive Chairperson	630k	S.O.	1948
Mr. Motti Farbstein	CEO and Chief Financial & Operating Officer	423k	S.O.	1964
Dr. Sari Fishman Ph.D.	Vice President of Business Development	340k	S.O.	1972
Dr. Ilan Cohn Ph.D.	Co-Founder & Director	S.O.	S.O.	1954
Dr. Stephen A. Harrison FACP, M.D.	Member of Clinical Advisory Board & Consulting Chief Medical Officer	S.O.	S.O.	S.O.

Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.

Description

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Can-Fite BioPharma Ltd. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.